How important is an evidence-based approach for cannabis-based products and medicines?

Sunday 20 June
16:15–16:45 CEST
Room Istanbul

Elinor Ben-Menachem
(Göteborgs Smärktklinik, Sweden)

Philippe Ryvlin
(Centre Hospitalier Universitaire Vaudois, Switzerland)

Cannabinoid science is an emerging and fascinating area of modern medicine, but the evidence landscape is complicated to navigate. Healthcare professionals, patients and members of the general public all face the challenge of dealing with many different forms of evidence, compounded further by potential misinformation.

This thought-provoking session will cover the debate surrounding the role of different types of evidence in medicine and will discuss how this applies to cannabinoids.

This symposium is organised and funded by GW Pharmaceuticals and is intended for a healthcare professional audience only.

Date of preparation: April 2021